Issue Simulation cannot count as regulatory evidence because shared validation standards do not exist

Summary

The strategic outlook states that regulators will need shared validation standards before simulation output can be accepted as evidence in drug approval, that transparency, reproducibility and quantified confidence become essential where no prior approval exists to compare against, and that such standards do not yet exist.